<DOC>
	<DOCNO>NCT00563706</DOCNO>
	<brief_summary>The primary purpose protocol establish efficacy , safety , tolerability vabicaserin ( SCA-136 ) use day capsule subject acute exacerbation schizophrenia .</brief_summary>
	<brief_title>Study Evaluating Vabicaserin Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Generally healthy , men woman , age 18 65 . Hospitalization acute exacerbation schizophrenia diagnosis schizophrenia establish great 1 year . Ability remain hospitalized duration screen period 4 week doubleblind treatment . Current Axis I primary psychiatric diagnosis schizophrenia ( DSMIVTR criterion ) . Current diagnosis history substance abuse dependence ( DSMIVTR criterion ) , include alcohol ( except nicotine ) , within 3 month baseline ( day 1 ) . Subjects take high chronic dos benzodiazepine screen evaluation , investigator 's judgment , would likely severe withdrawal symptom upon discontinuation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>